Merck KGaA takes charge of Bavencio in steady first quarter

11 May 2023
merck_kgaa_new_large

Germany’s Merck KGaA (MRK: DE) took in 5.3 billion euros ($5.8 billion) sales in the first quarter of 2023, a little short of many analysts’ expectations, a 1.8% increase from the same period of 2022.

With post-tax profits hitting 800 million euros, the earnings per share figure was 9.4% lower than in the first quarter of last year, at 1.83 euros.

Merck was propelled by a good performance in its healthcare division, which delivered significant increases in its business with new medicines.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical